Status | Study |
Recruiting |
Study Name: Sirolimus and Familial Adenomatous Polyposis (FAP) Condition: Adenomatous Polyposis Coli Date: 2017-03-21 Interventions: Drug: Sirolimus Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which |
Not yet recruiting |
Study Name: Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis. Condition: Familial Adenomatous Polyposis FAP Date: 2017-02-14 Interventions: Dietary Supplement: Wholistic Turmeric capsules |
Not yet recruiting |
Study Name: Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Condition: Attenuated Familial Adenomatous Polyposis Familial Date: 2016-11-10 Interventions: Drug: Erlotinib Hydrochloride |
Recruiting |
Study Name: Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program Condition: Attenuated Familial Adenomatous Polyposis Deleterious Familial Date: 2016-04-14 Interventions: Other: Chart Review Database queried for the presence of c |
Recruiting |
Study Name: Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) Condition: Familial Adenomatous Polyposis Date: 2016-01-02 Interventions: Procedure: Duodenoscopy and enteroscopy |
Not yet recruiting |
Study Name: Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Condition: FAP-Familial Adenomatous Polyposis Date: 2015-01-21 Interventions: Drug: Erythromycin Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is s |
Completed |
Study Name: Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW Condition: Adenomatous Polyposis Coli Date: 2014-04-02 Interventions: Drug: Bevacizumab-IRDye800CW I |
Completed |
Study Name: Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Condition: FAP-Familial Adenomatous Polyposis Date: 2012-11-26 Interventions: Drug: Erythromycin Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks |
Completed |
Study Name: The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study Condition: Familial Adenomatous Polyposis Date: 2012-10-31 Interventions: Drug: metformin Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-ap |
Active, not recruiting |
Study Name: Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Condition: Familial Adenomatous Polyposis Date: 2011-11-21 Interventions: Drug: Eflornithine plus Sulindac |